Joe Jimenez to replace Daniel Vasella as Novartis CEO

> Joe Jimenez to replace Daniel Vasella as Novartis CEO. Release

> Afferent Pharmaceuticals has appointed Bruce McCarthy as CEO. Release

> Pavan Handa has joined Antares Pharma as SVP of business development. Release

> Array BioPharma has announced that Bengt Bergstrom has joined the company as VP of clinical development. Release

> Shionogi Pharma has announced that Ray Russo has joined the company as VP, primary care business unit. Release

> Constellation Pharmaceuticals has tapped Garen Bohlin as the company's EVP. Bohlin will be responsible for Constellation's corporate operations and finance function. Release

> Lauren Sabella has joined Acorda Therapeutics as EVP, commercial development. Sabella will have responsibility for Acorda's commercial operations, including marketing, sales and managed markets. Release

> Malcolm MacCoss has been elected to Idera Pharmaceuticals' board of directors as a class II director. Release

> ProtoKinetix has appointed John Hutton to its scientific advisory board. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.